

A

11/18/97  
PTO-1082

Date: November 6, 1997  
Case Docket No. CMCC533  
Express Mail No. EM181252680US

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Transmitted herewith for filing is the patent application of  
Inventors: Merton Bernfield and Ofer Reizes  
For: Methods and Reagents for Regulating Obesity

Enclosed are:

- ☒ 16 sheets of informal drawings.
- ☐ An Assignment of the invention to \_\_\_\_\_
- ☐ A certified copy of a \_\_\_\_\_ application.
- ☒ An unexecuted Declaration
- ☐ A verified statement to establish small entity status under 37 CFR 1.9 and 37 CFR 1.27
- ☐ Request for Filing a Divisional Application under 37 CFR §1.60.


The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
FOR:	NO. FILED	NO. EXTRA
BASIC FEE		
TOTAL CLAIMS	25 -20 =	5
INDEP CLAIMS	5 -3 =	2
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENTED		

SMALL ENTITY			OTHER THAN A SMALL ENTITY	
RATE	FEE	OR	RATE	FEE
	\$395	OR		\$790
x 11 =	\$	OR	x 22 =	\$110
x 41 =	\$	OR	x 82 =	\$164
x135 =	\$	OR	x270 =	\$
TOTAL	\$	OR	TOTAL	\$1064

\* If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

- ☒ Please charge my Deposit Account No. 01-2507 in the amount of \$532.00. A duplicate copy of this sheet is enclosed.
- ☒ A check in the amount of \$532.00 is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 01-2507. A duplicate copy of this sheet is enclosed.
  - ☒ Any additional filing fees required under 37 CFR 1.16.
  - ☒ Any patent application processing fees under 37 CFR 1.17.
- ☒ The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 01-2507. A duplicate copy of this sheet is enclosed.
  - ☒ Any patent application processing fees under 37 CFR 1.17.
  - ☐ The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).
  - ☒ Any filing fees under 37 CFR 1.16 for the presentation of extra claims.

Respectfully submitted,  
  
Patrea L. Pabst, Reg. No. 31,284

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Merton Bernfield and Ofer Reizes

Serial No: Express Mail Label No.  
EM181252680US  
Filed: November 6, 1997 Date of Deposit  
November 6, 1997

For: METHODS AND REAGENTS FOR REGULATING OBESITY

BOX PATENT APPLICATION  
Assistant Commissioner  
for Patents  
Washington, D.C. 20231

EXPRESS MAIL TRANSMITTAL LETTER  
FOR PATENT APPLICATION AND CERTIFICATE OF MAILING

Sir:

Pursuant to 35 U.S.C. § 21(a) as amended by Public Law 97-247 and 37 C.F.R. § 1.10, Merton Bernfield and Ofer Reizes enclose for filing the attached patent application entitled "Methods and Reagents for Regulating Obesity", which claims benefit of U.S. Serial No. 60/030,758 entitled "Methods and Reagents for Regulating Obesity" filed November 6, 1996, by Merton Bernfield and Ofer Reizes. The application includes 1 page of Abstract, 36 pages of Specification, 2 pages of claims, 16 sheets of informal drawings, and an unexecuted Declaration. A check in the amount of \$ 532.00 to cover the filing fee is also enclosed. The executed Declaration, Assignment and Verified Statement Claiming Small Entity Status will be submitted shortly.

The Commissioner is hereby authorized to charge our deposit order account no. 01-2507 in the amount of \$ 532.00, which represents the difference between the filing fee for a large entity and a small entity.

"Methods and Reagents for Regulating Obesity"

Filed: November 6, 1997

By: Merton Bernfield and Ofer Reizes

EXPRESS MAIL TRANSMITTAL LETTER FOR PATENT APPLICATION

This application is being filed on November 6, 1997, by mailing the application to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231 via the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10. The Express Mail Label No. appears in the heading of this paper which is attached to the application papers pursuant to 37 C.F.R. § 1.10(B).

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 01-2507. To facilitate this process, applicants have enclosed a duplicate of this letter.

All correspondence concerning this application should be mailed to:

Patrea L. Pabst, Esq.  
ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, GA 30309-3450

Respectfully submitted,



---

Patrea L. Pabst  
Reg. No. 31,284

Date: November 6, 1997

ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 West Peachtree Street  
Atlanta, GA 30309-3450  
(404) 873-8794

"Methods and Reagents for Regulating Obesity"

Filed: November 6, 1997

By: Merton Bernfield and Ofer Reizes

EXPRESS MAIL TRANSMITTAL LETTER FOR PATENT APPLICATION

CERTIFICATE OF MAILING UNDER 37 CFR § 1.10

I hereby certify that this Express Mail Transmittal Letter for Patent Application and any documents referred to as attached therein are being deposited with the United States Postal Service on this date, November 6, 1997, in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, Mailing Label Number EM181252680US, addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: November 6, 1997

  
\_\_\_\_\_  
Jean Hicks

487123.1

**APPLICATION  
FOR  
UNITED STATES LETTERS PATENT  
BY  
MERTON BERNFIELD  
AND  
OFER REIZES  
FOR  
METHODS AND REAGENTS FOR REGULATING OBESITY**

## METHODS AND REAGENTS FOR REGULATING OBESITY

### Background of the Invention

The United States government has certain rights in this invention by virtue of National Institutes of Health grant Nos. RO1 HD06763-24,  
5 RO1 CA28735-15, UO1 HD28882-05 to Merton Bernfield, and F32 NS09649-02 to Ofer Reizes.

This application claims priority to U.S. Serial No. 60/030,758 entitled "Methods and Reagents for Regulating Obesity" filed November 6, 1996, by Merton Bernfield and Ofer Reizes.

10 Obesity is a well established risk factor for a number of potentially life-threatening diseases such as atherosclerosis, hypertension, diabetes, stroke, pulmonary embolism, and cancer. Furthermore, it complicates numerous chronic conditions such as respiratory diseases, osteoarthritis, osteoporosis, gall bladder disease, and dyslipidemias. The enormity of  
15 this problem is best reflected in the fact that death rates escalate with increasing body weight. More than 50% of all-cause mortality is attributable to obesity-related conditions once the body mass index (BMI) exceeds 30 kg/m<sup>2</sup>, as seen in 35 million Americans. (Lee1992. JAMA. 268:2045-2049). By contributing to greater than 300,000 deaths per year,  
20 obesity ranks second only to tobacco smoking as the most common cause of potentially preventable death. (McGinnis 1993 MA.270:2207-2212). Accompanying the devastating medical consequences of this problem is the severe financial burden placed on the health care system in the United States. The estimated economic impact of obesity and its associated  
25 illnesses from medical expenses and loss of income are reported to be in excess of \$68 billion/year. (Colditz G. 1992. Am J Clin Nutr. 55:503S-507S). This does not include the greater than \$30 billion per year spent on weight loss foods, products, and programs. (Wolf 1994. Pharmacoeconomics. 5:34-37).

30 A major reason for the long-term failure of established approaches is their basis on misconceptions and a poor understanding of the

mechanisms of obesity. Conventional wisdom maintained that obesity is a self-inflicted disease of gluttony. Comprehensive treatment programs, therefore, focused on behavior modifications to reduce caloric intake and increase physical activity using a myriad of systems. These methods have limited efficacy and are associated with recidivism rates exceeding 95%. (NIH Technology Assessment Conference Panel. 1993. *Ann Intern Med.* 119:764-770). Failure of short-term approaches, together with the recent progress made in elucidating the pathophysiology of obesity, have lead to a reappraisal of pharmacotherapy as a potential long-term, adjuvant treatment. (National Task Force on Obesity. 1996. *JAMA.* 276:1907-1915). The premise is that body weight is a physiologically controlled parameter similar to blood pressure and obesity is a chronic disease similar to hypertension. The goal of long-term (perhaps life long) medical therapy would be to facilitate both weight loss and subsequent weight maintenance in conjunction with a healthy diet and exercise. To assess this approach, the long-term efficacy of currently available drugs must be judged against that of non-pharmacological interventions alone. Currently, no single drug regimen emerges as superior in either promoting or sustaining weight loss. Although promising, the success of this approach is limited by the efficacy of currently available anorexiants drugs. Surgical interventions, such as gastric partitioning procedures, jejunoileal bypass, and vagotomy, have also been developed to treat severe obesity. (Greenway 1996. *Endo Metab Clin N Amer.* 25:1005-1027). Although these procedures induce similar rates of early weight loss as nonsurgical interventions, they have been shown to maintain a weight loss of up to 33% for more than 10 years. (Long 1994. *Diabetes Care.* 17:372-375). While still far from optimal, this is a substantial improvement over that achieved with behavioral and medical management alone. The superior long-term outcome with surgical procedures in attributed to the inherent permanence of the intervention which addresses the chronic nature of the disease. Although advantageous in the long run, the acute risk benefit ratio has reserved these invasive procedures for

morbidly obese patients according to the NIH consensus conference on obesity surgery (BMI > 40 kg/m<sup>2</sup>). (NIH Conference. 1991. Ann Intern Med. 115:956-961). Therefore, this is not an alternative for the majority of overweight patients unless and until they become profoundly obese and are suffering the attendant complications.

No one knows all of the mechanisms involved in regulation of weight gain, although it is believed that many genetic as well as environmental factors, including diet and exercise, play major, interrelated roles. A number of publications have reported the discovery of genes that have been "knocked out" or overexpressed in transgenic mice, resulting in affected animals becoming incredibly obese, or *vice versa*. See, for example, Ezzell, "Fat Times for Obesity Research: Tons of New Information, but How Does It All Fit Together" J. NIH Res. 7, 39-43 (October 1995). Researchers have reported the cloning of at least two distinct genes, Ob which encodes a protein "leptin" believed to cause weight reduction in obese animals, and Db, which is believed to cause weight gain in animals. Other genes which have been reported include the fat, tub, agouti, and melanocortin 4 receptor genes. Recent reviews relating to the insights regarding the mechanisms involved in obesity help to understand these complex pathways. See, for example, Trish Gura, Science 275, 752-753 (7 February 1997) and Jeffrey S. Flier, Proc. Natl. Acad. Sci. USA 94, 4242-4245 (April 1997). Leptin, discovered in 1994 by Jeffrey Friedman's team at Rockefeller University, NY, is a 16 kD protein produced by the obesity (ob) gene of mice. Homozygotes with defective ob genes are unable to reproduce, stay warm, or grow normally, and become grossly overweight. The receptor for leptin has now been identified and cloned. Defects in the receptor also result in grossly obese animals. The receptor is expressed in the brain primarily in four regions, including the arcuate nucleus. In humans, however, the linkage between obesity and overexpression of leptin does not seem to be closely correlated, and no individuals have been identified that have a mutated Ob receptor or gene. Another molecule which appears to be important in



weight control is the appetite-stimulating neurotransmitter referred to as neuropeptide Y or "NPY". NPY levels are elevated in animals with decreased levels of leptin. Genetic studies with knockout NPY and ob/ob animals indicate that NPY plays a role in, but is not a controlling factor, in obesity. Another line of research has implicated a role in obesity for the melanocortin receptor ("MCR"). Two MCRs, MCR3 and MCR4, are produced in the arcuate nucleus of the hypothalamus, a prime target of leptin action as well as of NPY production. Synthetic peptides mimicking melanocortins which bind to MCR-4 suppress feeding. Animals in which the gene encoding MCR-4 has been knocked out show the opposite behavior, exhibiting high weight gain and high NPY expression.

The genetic studies have clarified, but not definitively determined, the factors which are responsible for obesity, nor provided compounds for treatment or prevention of obesity.

It is therefore an object of the present invention to provide another method and means for regulating obesity.

It is a further object of the present invention to provide a method and means for screening for drugs which can regulate weight gain, alone or in combination with other drugs.

It is a still further object of the present invention to provide a method and means for studying the role of hormones and development on weight control.

#### **Summary of the Invention**

Lines of transgenic mice have been developed which preferentially express a syndecan in the regions of the hypothalamus which are known to be important in weight control. The animals were made using a construct including a cytomegalovirus promoter and the 3' untranslated region, including the polyadenylation site, of the bovine growth hormone gene, as well as cDNA encoding syndecan-1. The mice express the syndecan-1 transgene in many tissues, with expression in the brain occurring preferentially in their hypothalamus. The mice are

characterized by elevated levels of circulating syndecan-1 ectodomain and exhibit enormous weight gain after reaching sexual maturity. Transgenic animals in which stop codons have been inserted into the construct so that the syndecan is not expressed do not exhibit the same enormous weight gain. The animals have a relatively normal distribution of fat, are completely healthy and heterozygotes reproduce, and show other indicators associated with obesity in humans. The mice are useful in understanding the factors involved in weight regulation and in designing and screening for drugs which are involved in weight regulation and that can either enhance or reduce appetite and activity.

### Brief Description of the Drawings

Figure 1 is a schematic of body fat regulation.

Figures 2a and 2b are schematics of the constructs injected into fertilized oocytes. Figure 2a is the syndecan-1 expressing construct;

Figure 2b is the construct in which syndecan-1 is not expressed due to the inclusion of the stop codons.

Figures 3a and 3b are pedigrees of the transgenic animals with the A insert which causes overexpression of syndecan-1 in the hypothalamus, increased circulating levels of syndecan-1 ectodomain, and maturity onset obesity (Figure 3a) and the B insert (Figure 3b). Only heterozygote matings are shown and expected ratios were observed. Homozygotes are infertile.

Figures 4a and 4b are graphs showing body weight (g) (Figure 4a) and tail length (cm) (Figure 4b) over time, age in weeks, for male animals, demonstrating that maturity onset obesity correlates with genotype: normal wild type control (+/+), syndecan-1 transgenic heterozygotes (A/+), syndecan-1 transgenic homozygotes (A/A), and non-translatable syndecan-1 transgenic heterozygotes (C/+), (F/+) and (G/+). Values are the mean  $\pm$  SEM.

Figures 5a and 5b are graphs showing body weight (g) (Figure 5a) and tail length (cm) (Figure 5b) over time, age in weeks, for female animals, demonstrating that maturity onset obesity correlates with

genotype: normal wild type control (+/+), syndecan-1 transgenic heterozygotes (A/+) and (B/+), syndecan-1 transgenic homozygotes (A/A), and non-translatable syndecan-1 transgenic heterozygotes (C/+), (F/+), and (G/+).

5           Figure 6 is a graph of body length of transgenic mice, correlating body length measured from the tip of the nose to the anus in six month old mice for male and female normal wild type control mice (+/+) and syndecan-1 transgenic homozygotes (A/A), showing that transgenic mice are larger than normal wild type control mice at six months of age.

10           Figure 7 is a graph of hyperphagia in six week old and six month old syndecan-1 transgenic mice, measuring food intake (g) per week for female and male animals showing the correlation of food intake with genotype: normal wild type (+/+) and syndecan-1 transgenic homozygotes (A/A), demonstrating that transgenic mice are hyperphagic.

15           Figures 8a and 8b are graphs of leptin blood levels (ng/ml) correlated with weight (g) of male (Figure 8a) and female (Figure 8b) animals for controls (+/+), syndecan-1 transgenic heterozygotes (A/+) prior to maturity and obesity, obese syndecan-1 transgenic heterozygotes (A/+) , syndecan-1 transgenic homozygotes (A/A) prior to maturity and obesity, and obese syndecan-1 transgenic homozygotes (A/A).

20           Figures 9a and 9b are graphs of insulin blood levels (ng/ml) correlated with weight (g) of male (Figure 9a) and female (Figure 9b) animals for normal wild type controls (+/+), syndecan-1 transgenic heterozygotes (A/+) , and syndecan-1 transgenic homozygotes (A/A).

25           Figure 10 is a graph correlating genotype with glucose plasma levels (mg/dl) for male and female normal wild type controls (+/+), syndecan-1 transgenic heterozygotes (A/+) , and syndecan-1 transgenic homozygotes (A/A).

30           Figure 11 is a graph of plasma levels of soluble syndecan-1 ectodomain (ng/ml) in six month old overexpression mice, comparing normal wild type (+/+) and transgenic heterozygote mice: (A/+),

(B/+), (C/+), E/+), (F/+) and (G/+), showing that soluble syndecan-1 ectodomain is present in the plasma of transgenic mice.

Figures 12a and 12b are schematics of the syndecan interactions at the cell surface (Figure 12a) and soluble syndecans in the extracellular space (Figure 12b).

### Detailed Description of the Invention

Transgenic animals have been developed which are useful in screening for compounds and testing of compounds for the treatment of a wide range of eating disorders, including idiopathic obesity, anorexia nervosa, and cachexia due to disease. The latter is a significant clinical problem due to several cancers, cancer chemotherapy, chronic inflammatory diseases, rheumatoid and collagen diseases and chronic infections. Evidence accumulating over the past several years indicates that hormones, neuropeptides and neurotransmitters act on the hypothalamus to establish a "set point" that maintains a balance between feeding behavior and energy expenditure. A very small change in this set point can cause severe obesity or starvation. Expression of the syndecan-1 transgene in the hypothalamus appears to interfere with this set point mechanism. It is believed this occurs through interaction with the melanocortin-4 receptor (MC4R), which is known to be involved in weight regulation.

The cellular microenvironment contains many insoluble or immobilized as well as diffusible or circulating effector molecules that interact with cell surface receptors that signal cells to change behavior. Complex cellular behaviors such as those resulting in wound repair are influenced by a variety of soluble growth factors, cytokines, and insoluble extracellular matrix components. To exert their effects, many of these effector molecules must bind to the heparan sulfate chains that are at the surface of nearly all adherent cells (Ruoslahti and Yamaguchi, *Cell*, 64:867 (1991)). For example, interaction with cell surface heparan sulfate is required for cells to respond to the growth factors FGF-2

(Rapraeger, et al., *Science*, 252:1705 (1991); Yayon, et al. *Cell*, 64:841 (1991)) and HB-EGF (Higashiyama, et al., *J. Cell Bio.*, 122:933-940 (1993)), and to the matrix component fibronectin (Guan, et al. *Cell Reg.*, 2:951 (1991); Woods, et al., *Molec. Biol. Cell*, 4:605 (1993)). Indeed, 5 Guan, et al. (1991); Bernfield, et al., in *Annu. Rev. Cell Biol.*, G.E. Palade, B.M. Alberts, J.A. Spudich, Eds. (Annual Reviews Inc., Palo Alto, CA, 1992), 8:365-393); Jalkanen, et al., *Trends in Glyco-science and Glycotech*, 5:107 (1993); G. David, *FASEB J.*, 7:0123 (1993); and A.C. Rapraeger, *Curr. Opin. Cell Biol.*, 5:844 (1993)) have proposed that 10 cell surface heparan sulfate, which is derived mostly from the four members of the syndecan family of transmembrane proteoglycans (G. David, et al., *J. Cell Biol.*, 111:3165 (1990)), acts together with specific signaling receptors to mediate the cellular response to such effectors. Changes in the abundance of cell surface heparan sulfate probably 15 regulates the action of these effector molecules, yet it is not known how the amount of heparan sulfate at the cell surface is controlled.

Cell surface heparan sulfate mediates the activity of several growth factors, extracellular matrix components, proteases and other cellular effectors involved in wound repair. Syndecan-1, a major transmembrane 20 heparan sulfate proteoglycan, is induced transiently on mesenchymal cells during the repair of skin wounds. Accordingly, induction of syndecan-1 can influence this process. Syndecan-1 induction can trigger cellular behaviors such as proliferation and migration that are involved in wound repair due to its ability to bind and thus augment the action of heparin- 25 binding growth factors, including FGF-2, HB-EGF, and PDGF-AB, each found in repairing wounds. The expression of syndecan-1 is highly regulated *in vivo*. In mature tissues, syndecan-1 is expressed on the surface of epithelial cells but not on the surface of mesenchymal cells (K. Hayashi, et al., *J. Histochem. Cytochem.*, 35:1079 (1987)). However, 30 during cutaneous wound repair in the mouse, syndecan-1 is lost from the surface of the epithelial cells migrating into the wound and is induced on

the dermal endothelial cells and fibroblasts of the forming granulation tissue (K. Elenius, et al., *J. Cell Biol.*, 114:585 (1991)).

The syndecan core protein from mouse mammary epithelia was first cloned by Saunders, et al. 1989a). Other syndecans are also known and have now been cloned, including syndecan 2, 3 and 4. These syndecans constitute the syndecan family. They are characterized by a similar domain structure, highly conserved sequences, and a conserved exon organization in the genes studied to date. The molecular sizes of syndecan-1, -2, -3 and -4, are 311 amino acids, 384 amino acids, 201 amino acids, and 202 amino acids. Each protein contains a cluster of similar putative GAG attachment sites distal from the plasma membrane near the N-terminus of the mature protein: one site (or two in syndecan-3) is of the syndecan-type sequence and the other two (or three) sites are of the serglycin-type. Syndecan-1 and -3 contain putative GAG attachment sites that are absent in syndecan-2 and -4. The glycosaminoglycan (GAG) chains on the syndecans are critical to their functions. Variations in expression during development and by tissue, as well as the structure and composition, determine the role of the syndecans. However, little has been known other than in wound healing and cell-cell interaction until the studies described herein.

#### **I. Development of a Model of Body Fat Regulation**

Figure 1 is schematic of body fat regulation as it is understood based upon the information described herein. This diagram is based upon studies with transgenic mice originally developed from a single founder animal having a cDNA construct including a cytomegalovirus promoter and the 3' untranslated region, including the polyadenylation site, of the bovine growth hormone gene, as well as cDNA encoding syndecan-1. The detailed construction of this vector is described below, as are the pedigrees and results obtained with three distinct lines of animals, and additional lines containing the construct but with stop codons which prevent protein expression. A single founder was originally identified which generated two lines. Both syndecan-1 expressing lines show the

same phenotype: shedding of syndecan-1 into the blood, overexpression of syndecan-1 in the hypothalamus, overeating behavior and obesity in mature animals. Their morphology is otherwise normal. One line is characterized by a single insert "A". A second line is characterized by the same construct inserted at a separate location "B". The founder animal had both inserts, which segregated upon breeding, as discussed below. As described in more detail in the accompanying figures and tables, unlike normal non-transgenic littermates, the transgenic animals continue to gain weight following sexual maturity and cessation of linear growth, becoming markedly obese: homozygotes exceed twice normal weight at five months of age. The phenotype is dominant and is due to a defect in energy balance; food intake is excessive (double normal consumption), locomotor activity is reduced, fat pads, mammary glands, pancreas and liver are enlarged, carcass triglyceride is increased more than four-fold, and blood and urine glucose levels are elevated only in the overtly obese mice. Many organs overexpressed syndecan-1. In brain, both syndecan-1 proteoglycan (PG) and mRNA selectively localized to the paraventricular, arcuate, and lateral hypothalamic nuclei. In control lines (Syndecan-1 C, F and G), transgene mRNA is expressed in all tissues. In the hypothalamus, expression is observed in the arcuate, dorsomedial, lateral, suprachiasmatic, and supraoptic hypothalamic nuclei in a similar pattern in syndecan A, B and E lines.

#### **A. Design and Construct of Syndecan-1 Construct.**

The construct has two essential elements: (1) a promoter which localizes expression in the hypothalamus, especially in the paraventricular, arcuate, and lateral hypothalamic nuclei, and regulatory sequences required for processing of the transcript; (2) a nucleic acid molecule encoding a syndecan.

##### *1. Promoters and regulatory sequences*

Overexpression or preferential expression of the syndecan in the hypothalamus is believed to be an important aspect of the transgenic animals. This can be achieved using a promoter such as the truncated

cytomegalovirus promoter which is sold by Invitrogen, used in the construct depicted in Figures 2a and 2b. Other neurotropic promoters, many of which are commercially available, may also be useful.

Regulatory sequences required for processing of the transcript may also be included in the construct. A preferred example is the 3' untranslated region (UTR) of the bovine growth hormone gene, included in the Invitrogen vector, although any UTR can be used. It is believed the UTR stabilizes the transcript and may have an impact on localization.

## 2. *Syndecan encoding sequences.*

Nucleic acids encoding syndecan can be expressed in animals using known methods and procedures. For this purpose, syndecan transgene constructs can be made using known vectors and transcription and translation control sequences, and known principles and techniques of recombinant DNA. DNA encoding syndecan-1, homologs of syndecans, derivatives of syndecans, and chimeric syndecans, all useful for making syndecan transgene constructs, are described in U.S. Patent 5,486,599 to Saunders *et al.*, which is hereby incorporated by reference.

## 3. *Assembly of the syndecan-1 construct.*

Disclosed is an exemplary construct for expression of syndecan-1.

The syndecan transgene construct was made using expression vector pcDNA3 (Invitrogen). This vector contains a portion of the cytomegalovirus intermediate/early promoter/enhancer and the 3' untranslated region, including the polyadenylation site, of the bovine growth hormone gene. Vector pcDNA3 was cut with HindIII and a cDNA fragment encoding syndecan-1 was inserted between the expression elements in pcDNA3. The syndecan-1 cDNA fragment was an 1183 bp HindIII fragment including the syndecan-1 coding region, 10 bp of the syndecan-1 5' untranslated region, and about 200 bp of the syndecan-1 3' untranslated region. The resulting plasmid, shown in Figure 2a, contains a syndecan expression cassette of approximately 2500 bp MluI/DraIII fragment. The cassette includes about 600 bp of the cytomegalovirus (CMV) promoter, syndecan-1 cDNA sequence, and about 200 bp of the



3' untranslated region of the bovine growth hormone gene. Non-translatable constructs (syndecan C, F and G) were made by inserting three stop codons immediately following the signal peptide in the syndecan-1 cDNA, as shown in Figure 2b. The nucleic acid sequences encoding the different syndecans, including syndecan-1, are available from GENE BANK.

#### **B. Transgenic animals.**

The fragment shown in Figure 2b was excised from the plasmid and injected into fertilized FVB mouse oocytes. The injected oocytes were introduced into FVB mice resulting in transgenic offspring.

Although the study described herein used mice, it would clearly be routine to apply the same technology to other rodents such as rats or hamsters, or even to larger animals such as sheep, pigs, or goats where there may be commercial advantages in animals that continue to eat and gain weight to a significant degree more than their normal counterparts. For screening of most drugs, however, mice would be preferred due to the small size and rapid rate of breeding. Transgenic animals can be made either by microinjection or by embryonic stem cell manipulation.

The methods for constructing transgenic animals are well known and are usually either microinjection, where a gene is inserted, or embryonic stem cell manipulation, where a gene is to be knocked out.

Animals suitable for transgenic experiments can be obtained from standard commercial sources. These include animals such as mice and rats for testing of genetic manipulation procedures, as well as larger animals such as pigs, cows, sheep, goats, and other animals that have been genetically engineered using techniques known to those skilled in the art. These techniques are briefly summarized below based principally on manipulation of mice and rats.

##### **1. *Microinjection Procedures***

The procedures for manipulation of the embryo and for microinjection of DNA are described in detail in Hogan et al. Manipulating the mouse embryo, Cold Spring Harbor Laboratory, Cold

Spring Harbor, NY (1986), the teachings of which are incorporated herein. These techniques are readily applicable to embryos of other animal species, and, although the success rate is lower, it is considered to be a routine practice to those skilled in this art.

5           Female animals are induced to superovulate using methodology adapted from the standard techniques used with mice, that is, with an injection of pregnant mare serum gonadotrophin (PMSG; Sigma) followed 48 hours later by an injection of human chorionic gonadotrophin (hCG; Sigma). Females are placed with males immediately after hCG injection.  
10   Approximately one day after hCG, the mated females are sacrificed and embryos are recovered from excised oviducts and placed in Dulbecco's phosphate buffered saline with 0.5% bovine serum albumin (BSA; Sigma). Surrounding cumulus cells are removed with hyaluronidase (1 mg/ml). Pronuclear embryos are then washed and placed in Earle's  
15   balanced salt solution containing 0.5% BSA (EBSS) in a 37.5°C incubator with a humidified atmosphere at 5% CO<sub>2</sub>, 95% air until the time of injection.

          Randomly cycling adult females are mated with vasectomized males to induce a false pregnancy, at the same time as donor females. At  
20   the time of embryo transfer, the recipient females are anesthetized and the oviducts are exposed by an incision through the body wall directly over the oviduct. The ovarian bursa is opened and the embryos to be transferred are inserted into the infundibulum. After the transfer, the incision is closed by suturing.

## 25                           2.       *Embryonic Stem (ES) Cell Methods*

          Methods for the culturing of ES cells and the subsequent production of transgenic animals, the introduction of DNA into ES cells by a variety of methods such as electroporation, calcium phosphate/DNA precipitation, and direct injection are described in detail in  
30   Teratocarcinomas and embryonic stem cells, a practical approach, ed. E.J. Robertson, (IRL Press 1987), the teachings of which are incorporated herein. Selection of the desired clone of transgene-

containing ES cells is accomplished through one of several means. In cases involving sequence specific gene integration, a nucleic acid sequence for recombination with the gene or sequences for controlling expression thereof is co-precipitated with a gene encoding a marker such as neomycin resistance. Transfection is carried out by one of several methods described in detail in Lovell-Badge, in Teratocarcinomas and embryonic stem cells, a practical approach, ed. E.J. Robertson, (IRL Press 1987) or in Potter et al Proc. Natl. Acad. Sci. USA 81, 7161 (1984). Calcium phosphate/DNA precipitation, direct injection, and electroporation are the preferred methods. In these procedures, a number of ES cells, for example,  $0.5 \times 10^6$ , are plated into tissue culture dishes and transfected with a mixture of the linearized nucleic acid sequence and 1 mg of pSV2neo DNA (Southern and Berg, J. Mol. Appl. Gen. 1:327-341 (1982)) precipitated in the presence of 50 mg lipofectin in a final volume of 100  $\mu$ l. The cells are fed with selection medium containing 10% fetal bovine serum in DMEM supplemented with an antibiotic such as G418 (between 200 and 500  $\mu$ g/ml). Colonies of cells resistant to G418 are isolated using cloning rings and expanded. DNA is extracted from drug resistant clones and Southern blotting experiments using the nucleic acid sequence as a probe are used to identify those clones carrying the desired nucleic acid sequences. In some experiments, PCR methods are used to identify the clones of interest.

DNA molecules introduced into ES cells can also be integrated into the chromosome through the process of homologous recombination, described by Capecchi, (1989). Direct injection results in a high efficiency of integration. Desired clones are identified through PCR of DNA prepared from pools of injected ES cells. Positive cells within the pools are identified by PCR subsequent to cell cloning (Zimmer and Gruss, Nature 338, 150-153 (1989)). DNA introduction by electroporation is less efficient and requires a selection step. Methods for positive selection of the recombination event (i.e., neo resistance) and dual positive-negative selection (i.e., neo resistance and ganciclovir

resistance) and the subsequent identification of the desired clones by PCR have been described by Joyner et al., Nature 338, 153-156 (1989) and Capecchi, (1989), the teachings of which are incorporated herein.

5 Naturally cycling or superovulated females mated with males are used to harvest embryos for the injection of ES cells. Embryos of the appropriate age are recovered after successful mating. Embryos are flushed from the uterine horns of mated females and placed in Dulbecco's modified essential medium plus 10% calf serum for injection with ES cells. Approximately 10-20 ES cells are injected into blastocysts using a  
10 glass microneedle with an internal diameter of approximately 20  $\mu$ m.

Randomly cycling adult females are paired with vasectomized males. Recipient females are mated such that they will be at 2.5 to 3.5 days post-mating (for mice, or later for larger animals) when required for implantation with blastocysts containing ES cells. At the time of embryo  
15 transfer, the recipient females are anesthetized. The ovaries are exposed by making an incision in the body wall directly over the oviduct and the ovary and uterus are externalized. A hole is made in the uterine horn with a needle through which the blastocysts are transferred. After the transfer, the ovary and uterus are pushed back into the body and the  
20 incision is closed by suturing. This procedure is repeated on the opposite side if additional transfers are to be made.

### 3. *Identification of Transgenic Animals.*

Samples (1-2 cm of mouse tails) are removed from young animals. For larger animals, blood or other tissue can be used. To test for  
25 chimeras in the homologous recombination experiments, i.e., to look for contribution of the targeted ES cells to the animals, coat color has been used in mice, although blood could be examined in larger animals. DNA is prepared and analyzed by both Southern blot and PCR to detect transgenic founder ( $F_0$ ) animals and their progeny ( $F_1$  and  $F_2$ ).

30 Once the transgenic animals are identified, lines are established by conventional breeding and used as the donors for tissue removal and implantation using standard techniques for implantation into humans.

#### 4. *Insertion or modification of the genomic DNA*

These manipulations are performed by insertion of cDNA or genomic DNA into the embryo using microinjection or other techniques known to those skilled in the art such as electroporation. The DNA is selected on the basis of the purpose for which it is intended: to inactivate a gene, for example, a gene encoding an enzyme. The enzyme encoding gene can be modified by homologous recombination with a DNA for a defective enzyme, such as one containing within the coding sequence an antibiotic marker, which can then be used for selection purposes.

#### C. **Analysis of Transgenic Animals.**

Originally one founder mouse was identified by Southern blotting of BamHI fragmented tail genomic DNA probed with a CMV promoter probe. The CMV promoter probe allows clean Southern blotting results since mice do not naturally contain CMV sequences. The founder mouse exhibited three BamHI fragments hybridizing to the CMV promoter probe. The founder mouse was bred to non-transgenic mice and DNA from the resulting offspring were subjected to Southern blot analysis. These mice displayed either one of the original BamHI fragments (the A pattern) or the other two BamHI fragments (the B pattern). From this it could be concluded that the syndecan construct was inserted at two independently segregating locations in the genome of the founder mouse. The A insert has a single copy of the syndecan construct inserted (this was confirmed by isolation of the entire insertion region). The B insertion contains at least two copies of the syndecan construct inserted at one location.

Syndecan-1 expressing mice containing either construct exhibit an obese phenotype in adulthood, with mice containing the A insertion exhibiting greater obesity. It was determined that the A insertion does not insertionally inactivate any of the genes known to affect weight in mice. This, along with the location-independent obesity phenotype seen for both insertion sites, confirms that expression of the syndecan construct, rather than insertional mutagenesis is the likely cause of the obesity phenotype.

It was also determined that the pattern of expression of syndecan-1 in mice containing the two constructs was the same, although the B construct expressed syndecan-1 at a lower level than the A construct. Significantly, mice containing the A construct exhibit more profound obesity than mice containing the B construct.

1. *Pedigree Analysis.*

Figures 3a and 3b are pedigrees of the transgenic animals with the A insert which causes overexpression of syndecan-1 ectodomain in the hypothalamus, increased circulating levels of syndecan, and maturity onset obesity (Figure 3a) and the B insert (Figure 3b).

2. *Analysis of body weight, size, and blood levels.*

Figures 4a and 4b and 5a and 5b demonstrate that obesity increases with age and onset of maturity, and is correlated with genotype. Body weights and tail lengths of male (Figure 4a) and female (Figure 4b) mice were measured beginning at 10 days. Values are the mean  $\pm$  SEM. Data for males (Figure 4a and 4b) are from A, C, E, F and G lines, while data for females (Figures 5a and 5b) are from A, B, C, F and G lines: A, B, and E lines contain the identical syndecan-1 construct; the construct in the C, F and G lines was mutated by inserting three stop codons following the signal peptide, preventing translation. By 24 weeks of age transgenic line A homozygotes weighed an average of  $52 \pm 4$  g (n=6) in females ( $p < 0.0001$ ) and  $61 \pm 2$  g (n=5) in males ( $p < 0.0001$ ), hemizygotes showed an intermediate weight gain averaging  $37 \pm 2$  g (n=14) in females ( $p < 0.0001$ ) and  $49 \pm 2$  g (n=13) in males ( $p < 0.0001$ ). Control FVB and non-translatable transgenic mice (lines C, F, and G) weighed an average of  $21 \pm 1$  g (n=7) in females and  $31 \pm 1$  g (n=5) in males at 24 weeks of age. Weight difference in syndecan-1 overexpression mice is detectable by 7 weeks of age. Weight difference in syndecan-1 overexpression mice is detectable by 7 weeks with A line homozygote males weighing  $33.4 \pm 2.6$  g ( $p < 0.05$ ) and females  $24.2 \pm 0.9$  g ( $p < 0.05$ ), while control males weigh  $25.2 \pm 1.4$  g and females  $21.0 \pm$

1.1 g. Tail length showed no significance difference between any of the transgenic lines, indicating that their linear rate of growth was similar.

Body size of transgenic A line and control mice is shown in Figure 6. Body length was measured from the tip of the nose to the anus in 6 month old mice. A/A line mice are larger than their control by approximately 1 cm similar to observations made in the **agouti/MC4R** obese mice.

Food consumption in A/A and control +/+ mice at 6 weeks and 6 months of age is compared in Figure 7. Food consumption was monitored daily for two weeks in female and male mice at six weeks and six months of age. Data is presented on grams chow consumed per week. Both male and female A/A line mice consume more food than their control littermates and the hyperphagia increases with increased age and body weight.

Table 1 demonstrates the effect of the syndecan-1 on triglyceride levels. Results indicate that there is small increase in plasma triglyceride level in A line mice. Table 1 is an analysis of total carcass triglyceride in syndecan-1 A line mice. Syndecan-1 overexpression mice accumulated fat in all adipose tissue depots visualized by magnetic resonance imaging. Amount of fat varied between different genotypes and correlated with the obesity of the mice. Homozygote A male mice contained 3.6-fold more triglyceride than their controls while females contained 4.7-fold more triglyceride.

**TABLE 1: Carcass triglyceride analysis of syndecan-1 overexpression mice**

<u>Genotype (sex)</u>	<u>Weight (g)</u>	<u>Triglyceride (g)</u>
+/+ (male)	30.2 $\pm$ 1.9	4.7 $\pm$ 0.6
A/A (male)	48.3 $\pm$ 2.0	17.0 $\pm$ 1.5
+/+ (female)	27.1 $\pm$ 2.4	4.6 $\pm$ 0.7
A/A (female)	56.6 $\pm$ 3.3	21.9 $\pm$ 0.2

mean  $\pm$  SEM, n=4

age: males 5 months old

females 8 months old

p < 0.005 between +/+ and A/A mice.

Plasma leptin levels in syndecan-1 A line mice is shown in Figures 8a and 8b. Concentrations of leptin were analyzed from plasma of pre-obese (six weeks) and obese (six month) male (Figure 8a) and female (Figure 8b) mice by radioimmunoassay using a mouse leptin standard. As the mice become overtly obese, plasma levels of leptin elevate correlating with their weight. Prior to the onset of obesity, plasma levels of leptin are not significantly elevated when compared to control (+/+) mice.

Plasma insulin levels in syndecan-1 A line mice is shown in Figures 9a and 9b. Concentrations of insulin were analyzed from plasma of pre-obese (six weeks) and obese (six month) male (Figure 9a) and female (Figure 9b) mice by radioimmunoassay using a rat insulin standard. Plasma insulin levels are elevated only with the most severe obesity seen predominantly in the males. Prior to the onset of obesity, plasma levels of insulin are not significantly elevated when compared to control (+/+) mice.

Plasma glucose levels in syndecan-1 A line mice are shown in Figure 10. Glucose concentrations were assayed from plasma of control (+/+), heterozygote (A/+), and homozygote (A/A) mice. The level of plasma glucose is elevated only with severe obesity seen predominantly in the males.



No significant increase in corticosterone levels were observed in the syndecan-1 A line mice, which is similar to what has been observed in the **agouti/MC4R** obese mice and in marked contrast to levels observed in the **db** and **ob** obese mice.

5 Plasma levels of the soluble syndecan-1 ectodomain in overexpression mice is shown in Figure 11. Plasma from 6 month old transgenic mice was analyzed for the presence of syndecan-1. Ectodomain was detected only in lines A, B and E. Wildtype and nontranslatable mutant lines (C, F and G) showed no detectable syndecan-1.

10 1.

These results are summarized in Table 2 for syndecan-1 A line mice, comparing plasma glucose, insulin, leptin and corticosterone in syndecan-1 A line and control (+/+) mice measured at 6 weeks and 6 months.

**Table 2: Plasma constituents in syndecan-1 A line mice**

	<u>Glucose</u> (mg/dl)	<u>Insulin</u> (ng/ml)	<u>Leptin</u> (ng/ml)	<u>Corticosterone</u> (ng/ml)
<b><u>6 week males</u></b>				
+/+ (n=5)	204 ± 21	1.2 ± 0.1	2.8 ± 0.8	n.d.
A/A (n=5)	250 ± 45	1.2 ± 0.4	3.2 ± 0.5	n.d.
<b><u>6 week females</u></b>				
+/+ (n=5)	180 ± 25	1.5 ± 0.5	1.9 ± 0.4	n.d.
A/A (n=5)	190 ± 50	1.9 ± 0.4	1.8 ± 0.2	n.d.
<b><u>6 mos. males</u></b>				
+/+ (n=6)	176 ± 25 *	1.1 ± 0.2 ‡	3.1 ± 0.2 *	16.5 ± 3.0
A/A (n=5)	508 ± 16 *	64.3 ± 19 ‡	17.0 ± 1.2 *	20.0 ± 0.7
<b><u>6 mos females</u></b>				
+/+ (n=7)	126 ± 5 †	0.4 ± 0.2 †	2.5 ± 0.5 ‡	29 ± 8.0
A/A (n=6)	248 ± 54 †	9.4 ± 3.0 †	28.4 ± 5.5 ‡	30 ± 8.0

n.d. = not determine

† = p<0.05

‡ = p<0.005

\* = p<0.0001

As shown above, leptin levels correlate with obesity, hyperinsulinemia and hyperglycemia are markedly pronounced in the obese (6 months) males, while corticosterone is not elevated.

Expression analysis was performed using monoclonal 281-2 by  
5 immunohistochemical analysis of tissues. The results are shown in **Table 3**. Unless otherwise noted staining was observed along the cell surface. \* indicates intracellular localization.

Accepted for publication

TABLE 3: Localization of syndecan-1 in +/+ and A/A mice.

Tissue	level		Cell Type	Tissue	level		Cell type
	Expression	level			Expression	level	
Heart	-	-	not detected	Heart	+++	+++	cardiac muscle cell*
Kidney	-	-	not detected	Kidney	+++	+++	kidney tubule
Pancreas	-	-	not detected	Pancreas	+++	+++	acinus, islets of Langerhans
Skeletal Muscle	-	-	not detected	Skeletal Muscle	+++	+++	muscle cell*
Adrenal gland	-	-	not detected	Adrenal gland	++	++	medulla
Skin	+++	+++	epidermis	Skin	+++	+++	epidermis
Lung	+	+	type II cell?	Lung	+	+	type II cell?
Spleen	+	+	white pulp, ? cell	Spleen	+	+	whitepulp, ? cell
Liver	+	+	sinusoid, endothelial cell	Liver	+	+	sinusoid, endothelial cell ?
Thyroid	-	-	not detected	Thyroid	-	-	not detected
Testes	+	+	epithelial cell	Testes	+	+	epithelial cell
Epididymis	+	+	epithelial cell	Epididymis	+	+	epithelial cell
Seminal Vesicles	+	+	epithelial cell	Seminal Vesicles	++	++	epithelial cell
Fat	-	-	not detected	Fat	-	-	not detected
Bladder	+++	+++	epithelial cell	Bladder	+++	+++	epithelial cell

Table 3 shows tissues which express syndecan-1 in the overexpression mice. With the exception of skin and bladder, the level of expression the transgenic **A** and **B** line tissues was much greater than the controls (+/+). Syndecan-1 was not detected in the brain, heart, kidney, pancreas, skeletal muscle, and adrenal gland of control mice.

Immunohistochemical and *in situ* hybridization analyses of syndecan-1 expression in the hypothalamic regions of syndecan-1 **A/A**, **B/+**, **C/C**, and control mice show that the transgene is expressed in similar nuclei of the hypothalamus indicating that transgene expression is independent of the phenotype. Thus elements in the transgene are sufficient to drive expression in the brain. Expression was observed in the paraventricular, suprachiasmatic, lateral, dorso-medial, and arcuate nuclei of the hypothalamus. Syndecan-1 transgene is expressed in the hypothalamus regions that regulate energy balance.

In summary, "syndtrophin" ("syndein" Greek for "to bind together"; "trophus" Greek for "round and well nourished") mice are similar to obese humans. They exhibit normal development, growth and fertility. The results demonstrate that, prior to obesity, food intake is excessive, blood levels of soluble ectodomain are elevated, and the syndecan misexpression is localized in hypothalamic regions that control energy balance. Onset of obesity occurs after sexual maturity and affects all adipose tissue sites.

TABLE 4: Characteristics of mouse obesity syndromes

Mouse mutant	Inheritance	obesity onset	elevated leptin	elevated insulin	hyperglycemia	elevated corticosterone	increased body size	hyperphagia
<i>ob/ob</i>	recessive	early	n/a	@4 weeks	strain dependent	yes	no	high
<i>db/db</i>	recessive	early	yes	@ 10 days	strain dependent	yes	no	high
<i>agouti</i>	dominant	adult	yes	male > females @ 2 mos	males only	no	yes	mild
<i>mc4R-ko</i>	semi-dominant	adult	yes	males > females @2 mos	males only	no	yes	mild
<i>FVB/N-TgN (synd-1)aMB</i>	dominant	adult	yes	males > females @6 mos	males only	no	yes	high in old mild in 6 weeks

Table 4 is a comparison of mouse obesity syndromes. This comparison attempts to illustrate the similarities and differences between the obese mouse mutants and the syndecan-1 obese mouse. It is clear that the syndecan-1 mouse is quite similar physiologically to the **agouti/MC4R** obese mice. It is likely that the syndecan-1 protein impinges either directly or indirectly on the **agouti/MC4R signaling cascade**.

## II. Development of Weight Regulating Compounds

Heparan sulfate proteoglycans (HSPGs) alter the activity of many proteins, including extracellular matrix (ECM) components, growth factors, antiproteases, and lipases, as shown in Figure 12a. Figure 12a is a diagrammatic representation of syndecan functions at the cell surface. Syndecans can bind extracellular molecules as receptors or as co-receptors and/or signal transducing receptors. Shown in the figure are examples of syndecans acting as receptors (e.g., lipoprotein lipase internalization), or co-receptors for the action of growth factors (e.g., FGF signaling) and extracellular matrix components (e.g., adhesion to fibronectin with actin cytoskeleton reorganization). The syndecan family of transmembrane PGs includes most of the HS at cell surfaces but these PGs may also be shed, potentially becoming paracrine effectors, as shown in Figure 12b. Figure 12b is a diagrammatic representation of putative function of soluble syndecans. The syndecan ectodomain can be cleaved near the plasma membrane and released into the extracellular milieu as a soluble proteoglycan. The shed syndecan can activate or inhibit the action of its ligands on adjacent cells, thus acting as a paracrine effector. The heparan sulfate chains may be partially degraded by extracellular heparanases at inflammatory sites, releasing oligosaccharides that can act as mediators.

The transgenic mice were originally developed to assess shedding *in vivo* of overexpressed syndecan-1 under the control of the 5'-human CMV promoter and the bovine growth hormone 3'-UTR in FVB mice. The overexpressed syndecan-1 could act centrally by inhibiting a known satiety factor (such as FGF-2 and melanocortins), or peripherally by enhancing activities that mobilize fat such as lipoprotein lipase, or both.

It is also significant that the transgene is ectopically expressed in the brain, in the hypothalamic centers that regulate body weight but in no other brain sites. Specifically, the arcuate, paraventricular, dorsomedial and lateral hypothalamic nuclei express both the transgene mRNA and syndecan-1. This misexpression increases as the mice develop post-natally. In contrast, normal mice have no or very low levels of expression of syndecan-1 and syndecan-3, respectively, in the post-natal brain.

The hypothalamic expression of the transgene may cause the syndecan-1 proteoglycan to bind a satiety factor that acts downstream of leptin, causing hyperphagia and lethargy. Based on these findings, compounds can be designed and tested which will either enhance or reduce appetite and activity. These are then useful as treatments for a wide range of eating disorders, including idiopathic obesity, anorexia nervosa, and cachexia due to disease, for example, cancer, cancer chemotherapy, chronic inflammatory diseases, rheumatoid and collagen diseases and chronic infections.

Understanding the mechanism of action of these animals' weight gains and having the animals to test potential treatments makes available means both for increasing appetite as well as suppressing appetite, and concordant weight gain. This not only has medical applications but may be of use in agriculture, where animals can be treated with a compound which mimics a syndecan and which can pass through the blood brain barrier. These compounds should act in a manner analogous to the growth factors currently in wide usage.

These mice show that syndecan-1 is shed and that HSPGs can alter energy balance, providing a new genetic model for maturity onset obesity that resembles the human condition. The phenotype mimics the human condition in several respects. The obesity begins only after sexual maturity, fat accumulates in all adipose tissue depots, the mice eat excessively and are less active physically, but otherwise show no abnormalities, including normal fertility in heterozygotes. Thus, these

mice become fat by the same route that most people do: they eat too much. Blood levels of the hormones leptin and insulin are elevated and correlate with body fat, but only the most obese males are diabetic. The normal syndecan-1 gene is expressed at the cell surfaces of many tissues but not in the post-natal brain. The transgene is expressed in most tissues and blood levels of the soluble syndecan-1 extracellular domain are markedly elevated in these mice. It is significant that these high blood levels precede the onset of obesity.

It should be understood that while the studies described above utilize syndecan-1, it will be apparent to those skilled in the art of syndecans that other syndecans -2, -3, and -4 which constitute the syndecan family (referred to herein merely as "syndecans") and proteoglycan molecules such as glypican could be substituted for syndecan-1.

These compounds are basically grouped as follows:

A. Regulators of feeding behavior.

Agents that mimic or destroy or modify syndecan can act as agonists or antagonists, inhibiting a satiety factor or stimulating a feeding factor. These agents can be similar to the intact proteoglycan, the glycosaminoglycan chains such as heparan sulfate or chondroitin sulfate, the core protein, or oligosaccharides, organic glycomimetics, or enzymes that degrade the glycosaminoglycan chains.

B. Regulators of syndecan expression.

Agents that turn on syndecan expression will have the same effects as the syndecan mimicking agents. An example is the antibacterial peptides referred to as synducin, PR-39, described in PCT/US95/12080 "Synducin Mediated Modulation of Tissue Repair" by Children's Medical Center Corporation. Another example would be the oligonucleotides now in use which inhibit expression, for example, antisense, ribozymes, or external guide sequences for RNAase P.



C. Targeting specific brain regions.

A DNA construct that results in expression of the syndecan transgene in those areas of the hypothalamus responsible for the regulation of body weight and energy balance. The construct described  
5 herein must include a transcriptional activator specific for that region of the brain, since inserts at two segregating loci both produced the same phenotype. Additionally, a control construct (lines C, F and G) also express transgene mRNA in these hypothalamic centers. The transcriptional activator sequence can therefore also be a target to increase  
10 or decrease expression in the hypothalamus of syndecan or other known genes involved in weight regulation.

D. Hormonal regulators.

It is apparent from the data that hormones must play a role in syndecan expression and obesity in mature animals. Accordingly, one  
15 could also alter the pathway in which the hormones expressed as a result of the syndecan expression in the hypothalamus are regulated.

The compounds described above can be designed based on information already known to those skilled in the art, such as the DNA sequence encoding the syndecans, the protein and carbohydrate structures  
20 of the syndecans and other proteoglycans, and then routinely screened using the transgenic mice described herein or mice developed in a similar way. Useful compounds are designed based on methods known to those skilled in the art. The criteria for assessing response to therapeutic modalities employing these compounds is dictated by the specific  
25 condition and will generally follow standard medical practices.

*Random generation of binding molecules.*

Molecules with a given function, catalytic or ligand-binding, can be selected for from a complex mixture of random molecules in what has been referred to as "in vitro genetics" (Szostak, TIBS 19:89, 1992). One  
30 synthesizes a large pool of molecules bearing random and defined sequences and subjects that complex mixture, for example, approximately  $10^{15}$  individual sequences in 100  $\mu$ g of a 100 nucleotide RNA, to some

selection and enrichment process. For example, by repeated cycles of affinity chromatography and PCR amplification of the molecules bound to the ligand on the column, Ellington and Szostak (1990) estimated that 1 in  $10^{10}$  RNA molecules folded in such a way as to bind a given ligand.

5 DNA molecules with such ligand-binding behavior have been isolated (Ellington and Szostak, 1992; Bock et al, 1992).

### *Computer assisted drug design*

Computer modeling technology allows visualization of the three-dimensional atomic structure of a selected molecule and the rational  
10 design of new compounds that will interact with the molecule. The three-dimensional construct typically depends on data from x-ray crystallographic analyses or NMR imaging of the selected molecule. The molecular dynamics require force field data. The computer graphics systems enable prediction of how a new compound will link to the target  
15 molecule and allow experimental manipulation of the structures of the compound and target molecule to perfect binding specificity. Prediction of what the molecule-compound interaction will be when small changes are made in one or both requires molecular mechanics software and computationally intensive computers, usually coupled with user-friendly,  
20 menu-driven interfaces between the molecular design program and the user.

Examples of molecular modelling systems are the CHARMM and QUANTA programs, Polygen Corporation, Waltham, MA. CHARMM performs the energy minimization and molecular dynamics functions.  
25 QUANTA performs the construction, graphic modelling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

A number of articles review computer modeling of drugs  
30 interactive with specific proteins, such as Rotivinen, et al., 1988 Acta Pharmaceutica Fennica 97, 159-166; Ripka, New Scientist 54-57 (June 16, 1988); McKinaly and Rossman, 1989 Annu. Rev. Pharmacol.

Toxicol. 29, 111-122; Perry and Davies, QSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, inc. 1989); Lewis and Dean, 1989 Proc. R. Soc. Lond. 236, 125-140 and 141-162; and, with respect to a model receptor for nucleic acid

5 components, Askew, et al., 1989 J. Am. Chem. Soc. 111, 1082-1090. Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc., Pasadena, CA., Allelix, Inc., Mississauga, Ontario, Canada, and Hypercube, Inc., Cambridge, Ontario. Although these are primarily designed for  
10 application to drugs specific to particular proteins, they can be adapted to design of drugs specific to regions of DNA or RNA, once that region is identified.

Although described above with reference to design and generation of compounds which could alter binding, one could also screen libraries  
15 of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds which are inhibitors or activators of syndecan expression.

Nucleotide molecules which bind either syndecan, syndecan components or genes regulating expression of or encoding syndecan can  
20 be generated *in vitro*, and then inserted into cells. Oligonucleotides can be synthesized on an automated synthesizer (e.g., Model 8700 automated synthesizer of Milligen-Bioscience, Burlington, MA or ABI Model 380B). (see, e.g., Offensperger et al., 1993 EMBO J. 12, 1257-1262 (*in vivo* inhibition of duck hepatitis B viral replication and gene expression by  
25 antisense phosphorothioate oligodeoxynucleotides); Rosenberg et al., PCT WO 93/01286 (synthesis of sulfurthioate oligonucleotides); Agrawal et al., 1988 Proc. Natl. Acad. Sci. USA 85, 7079-7083 (synthesis of antisense oligonucleoside phosphoramidates and phosphorothioates to inhibit replication of human immunodeficiency virus-1); Sarin et al., 1989  
30 Proc. Natl. Acad. Sci. USA 85, 7448-7794 (synthesis of antisense methylphosphonate oligonucleotides); Shaw et al., 1991 Nucleic Acids Res 19, 747-750 (synthesis of 3' exonuclease-resistant oligonucleotides

containing 3' terminal phosphoroamidate modifications); incorporated herein by reference). To reduce susceptibility to intracellular degradation, for example by 3' exonucleases, a free amine can be introduced to a 3' terminal hydroxyl group of oligonucleotides without loss of sequence binding specificity (Orson et al., 1991). Furthermore, more stable triplexes are formed if any cytosines that may be present in the oligonucleotide are methylated, and also if an intercalating agent, such as an acridine derivative, is covalently attached to a 5' terminal phosphate (e.g., via a pentamethylene bridge); again without loss of sequence specificity (Maher et al., (1989); Grigoriev et al., 1992).

Methods to produce or synthesize oligonucleotides are well known in the art. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see e.g., Sambrook et al., Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System 1Plus DNA synthesizer (see also, Ikuta et al., in Ann. Rev. Biochem. 1984 53, 323-356 (phosphotriester and phosphite-triester methods); Narang et al., in Methods Enzymol., 65, 610-620 (1980) (phosphotriester method).

#### *Preparation of Peptides*

Proteins can be expressed recombinantly and cleaved by enzymatic digest, expressed from a sequence encoding a peptide, or synthesized using standard techniques. It is a routine matter to make appropriate peptides, test for binding or inhibition, and then utilize. The peptides can be as short as twenty six amino acids in length and up to 57 amino acids, and are easily prepared by standard techniques. They can also be modified to increase *in vivo* half-life, by chemical modification of the amino acids or by attachment to a carrier molecule or inert substrate.

The peptides can also be conjugated to a carrier protein such as keyhole limpet hemocyanin by its N-terminal cysteine by standard procedures such as the commercial Inject kit from Pierce Chemicals or expressed as a fusion protein, which may have increased efficacy. These

methods are known to those skilled in the art. An example is the solid phase synthesis described by J. Merrifield, 1964 J. Am. Chem. Soc. 85, 2149, used in U.S. Patent No. 4,792,525, and described in U. S. Patent No. 4,244,946, wherein a protected alpha-amino acid is coupled to a  
5 suitable resin, to initiate synthesis of a peptide starting from the C-terminus of the peptide. Other methods of synthesis are described in U.S. Patent No. 4,305,872 and 4,316,891. These methods can be used to synthesize peptides having identical sequence to the receptor proteins described herein, or substitutions or additions of amino acids, which can  
10 be screened for activity as described above.

The peptide can also be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic  
15 acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted  
20 ethanolamines.

Peptides containing cyclopropyl amino acids, or amino acids derivatized in a similar fashion, can also be used. These peptides retain their original activity but have increased half-lives *in vivo*. Methods known for modifying amino acids, and their use, are known to those  
25 skilled in the art, for example, as described in U.S. Patent No. 4,629,784 to Stammer.

#### *Carbohydrate Reagents*

Carbohydrate components (the O-glycan structures or components thereof) of the ligand or the antibodies, in an appropriate pharmaceutical  
30 carrier, can be administered intramuscularly, intraperitoneally, subcutaneously, orally, as the carbohydrate, conjugated to a carrier

molecule, or in a drug delivery device. The carbohydrate can be modified chemically to increase its in vivo half-life.

The carbohydrate can be isolated from cells expressing the carbohydrate, either naturally or as a result of genetic engineering as described in the transfected mammalian cell examples, or, preferably, by synthetic means. These methods are known to those skilled in the art. In addition, a large number of additional glycosyltransferases have been cloned (J.C. Paulson and K.J. Colley, J. Biol. Chem. 264:17615-17618, 1989). Accordingly, workers skilled in the art can use a combination of synthetic chemistry and enzymatic synthesis to make pharmaceuticals or diagnostic reagents.

### *Antibodies*

#### *In vivo Immunization of Animals*

Animals such as mice may be immunized by administration of an amount of immunogen effective to produce an immune response. Preferably a mouse is subcutaneously injected in the back with 100 micrograms of antigen, followed three weeks later with an intraperitoneal injection of 100 micrograms of immunogen with adjuvant, most preferably Freund's complete adjuvant. Additional intraperitoneal injections every two weeks with adjuvant, preferably Freund's incomplete adjuvant, may be necessary until the property titer in the mouse's blood is achieved. In order to use the mice for fusion and hybridoma production, a titer of at least 1:5000 is preferred, and a titer of 1:100,000 or more is most preferred.

#### *In vitro Immunization*

The technique of *in vitro* immunization of human lymphocytes is frequently employed to generate a large variety of human monoclonal antibodies, since deliberate *in vivo* priming of humans with many antigens of interest is not feasible until approval by the Food and Drug Administration has been obtained. Techniques for *in vitro* immunization of human lymphocytes are well known to those skilled in the art. See, e.g., T. Inai, *et al.*, Histochemistry (German), 99(5):335-362 (May

1993); A. Mulder, *et al.*, Hum. Immunol., 36(3):186-192 (Mar. 1993);  
H. Harada, *et al.*, J. Oral Pathol. Med. (Denmark), 22(f):145-152 (April  
1993); N. Stauber, *et al.*, J. Immunol. Methods (Netherlands),  
161(2):157-168 (May 26, 1993); and S. Venkateswaran, *et al.*,  
5 Hybridoma, 11(6):729-739 (Dec. 1992), which are incorporated herein by  
reference. These techniques can be used to produce antigen-reactive  
human monoclonal antibodies, including antigen-specific IgG, and IgM  
human monoclonal antibodies.

#### Humanization of Antibodies

10 Because the methods for immunizing animals yield antibody which  
is not of human origin, the antibodies could elicit an adverse effect if  
administered to humans. Methods for "humanizing" antibodies, or  
generating less immunogenic fragments of non-human antibodies, are well  
known. A humanized antibody is one in which only the antigen-  
15 recognized sites, or complementarity-determining hypervariable regions  
(CDRs) are of non-human origin, whereas all framework regions (FR) of  
variable domains are products of human genes. These "humanized"  
antibodies present a less xenograft-like rejection stimulus when introduced  
to a human recipient.

20 To accomplish humanization of a selected mouse monoclonal  
antibody, the CDR grafting method described by Daugherty, *et al.*, Nucl.  
Acids Res., 19:2471-2476 (1991), incorporated herein by reference, may  
be used. Briefly, the variable region DNA of a selected animal  
recombinant anti-idiotypic ScFv is sequenced by the method of Clackson,  
25 T., *et al.*, Nature, 352:624-688, 1991, incorporated herein by reference.  
Using this sequence, animal CDRs are distinguished from animal  
framework regions (FR) based on locations of the CDRs in known  
sequences of animal variable genes. Kabat, H.A., *et al.*, Sequences of  
Proteins of Immunological Interest, 4th Ed. (U.S. Dept. Health and  
30 Human Services, Bethesda, MD, 1987). Once the animal CDRs and FR  
are identified, the CDRs are grafted onto human heavy chain variable  
region framework by the use of synthetic oligonucleotides and polymerase

chain reaction (PCR) recombination. Codons for the animal heavy chain CDRs, as well as the available human heavy chain variable region framework, are built in four (each 100 bases long) oligonucleotides. Using PCR, a grafted DNA sequence of 400 bases is formed that encodes  
5 for the recombinant animal CDR/human heavy chain FR protection.

The immunogenic stimulus presented by the monoclonal antibodies so produced may be further decreased by the use of Pharmacia's (Pharmacia LKB Biotechnology, Sweden) "Recombinant Phage Antibody System" (RPAS), which generates a single-chain Fv fragment (ScFv)  
10 which incorporates the complete antigen-binding domain of the antibody. In the RPAS, antibody variable heavy and light chain genes are separately amplified from the hybridoma mRNA and cloned into an expression vector. The heavy and light chain domains are co-expressed on the same polypeptide chain after joining with a short linker DNA which codes for a  
15 flexible peptide. This assembly generates a single-chain Fv fragment (ScFv) which incorporates the complete antigen-binding domain of the antibody. Compared to the intact monoclonal antibody, the recombinant ScFv includes a considerably lower number of epitopes, and thereby presents a much weaker immunogenic stimulus when injected into  
20 humans.

#### *Pharmaceutical Compositions*

The compounds described above are preferably administered in a pharmaceutically acceptable vehicle. Suitable pharmaceutical vehicles are known to those skilled in the art. Suitable pharmaceutical vehicles for  
25 administration to a patient are known to those skilled in the art. For parenteral administration, the carbohydrate will usually be dissolved or suspended in sterile water or saline. For enteral administration, the carbohydrate will be incorporated into an inert carrier in tablet, liquid, or capsular form. Suitable carriers may be starches or sugars and include  
30 lubricants, flavorings, binders, and other materials of the same nature. The carbohydrate can also be administered locally at a wound or inflammatory site by topical application of a solution or cream.



Alternatively, the carbohydrate may be administered in, on or as part of, liposomes or microspheres (or microparticles). Methods for preparing liposomes and microspheres for administration to a patient are known to those skilled in the art. U.S. Patent No. 4,789,734 describe  
5 methods for encapsulating biological materials in liposomes. Essentially, the material is dissolved in an aqueous solution, the appropriate phospholipids and lipids added, along with surfactants if required, and the material dialyzed or sonicated, as necessary. A good review of known methods is by G. Gregoriadis, Chapter 14. "Liposomes", Drug Carriers  
10 in Biology and Medicine pp. 287-341 (Academic Press, 1979).  
Microspheres formed of polymers or proteins are well known to those skilled in the art, and can be tailored for passage through the gastrointestinal tract directly into the bloodstream. Alternatively, the carbohydrate can be incorporated and the microspheres, or composite of  
15 microspheres, implanted for slow release over a period of time, ranging from days to months. See, for example, U.S. Patent No. 4,906,474, 4,925,673, and 3,625,214. The compounds can also be administered locally by topical application of a solution, cream, gel, or polymeric material (for example, a Pluronic™, BASF).

We claim:

1. A non-human transgenic animal having binding to the melanocortin 4 receptor function inactivated.
2. The animal of claim 1 wherein the animal expresses a molecule from a genetically engineered construct stably integrated into its genome wherein the molecule binds to the melanocortin 4 receptor.
3. The animal of claim 2 wherein the molecule is a syndecan.
4. The animal of claim 2 wherein the molecule is expressed preferentially in the hypothalamus.
5. The animal of claim 4 having incorporated therein a construct including a cytomegalovirus promoter or portion thereof including the intermediate/early enhancer.
6. The animal of claim 1 having the genotype FVB/N-TgN(synd-1).
7. A genetically engineered construct for making a transgenic animal comprising a promoter and a nucleic acid molecule encoding a syndecan, wherein the syndecan is preferentially expressed in the hypothalamus.
8. The construct of claim 7 wherein the promoter is the cytomegalovirus promoter or a functional portion thereof including the intermediate/early enhancer.
9. The construct of claim 7 wherein the syndecan is syndecan-1.
10. A method for screening for compounds which can alter body weight comprising  
administering a compound to a non-human transgenic animal having binding to the melanocortin 4 receptor function inactivated, and  
observing whether there is a change in body weight over a period of time.
11. The method of claim 10 wherein the animal expresses a molecule from a genetically engineered construct stably integrated into its genome wherein the molecule binds to the melanocortin 4 receptor.
12. The method of claim 10 wherein the molecule is a syndecan.
13. The method of claim 11 wherein the molecule is expressed preferentially in the hypothalamus.

14. The method of claim 13 wherein the animal has incorporated therein a construct including a cytomegalovirus promoter or portion thereof including the intermediate/early enhancer.
15. The method of claim 14 wherein the animal has the genotype FVB/N-TgN(synd-1).
16. A composition for altering body weight obtained by administering a compound to an animal as defined by any of claims 1-6 and observing a change in body weight over a period of time.
17. The composition of claim 16 wherein the compound is a syndecan or a mimic thereof of its binding ability.
18. The composition of claim 17 wherein the compound can pass the blood brain barrier.
19. A method for regulating body weight comprising administering to the animal a compound which interferes with melanocortin 4 receptor function.
20. The method of claim 19 wherein the compound is a syndecan or a mimic thereof of its binding ability.
21. The method of claim 20 wherein the compound can pass the blood brain barrier.
22. The method of claim 19 wherein the compound is administered by genetically engineering the animal to express a compound blocking binding to melanocortin 4 receptor.
23. The method of claim 19 wherein the compound is administered as a pharmaceutically acceptable composition.
24. The method of claim 19 wherein the animal has a wasting disorder.
25. The method of claim 24 wherein the disorder is selected from the group consisting of idiopathic obesity, anorexia nervosa, and cachexia due to disease, for example, cancer, cancer chemotherapy, chronic inflammatory diseases, rheumatoid and collagen diseases and chronic infections.

## METHODS AND REAGENTS FOR REGULATING OBESITY

### Abstract of the Invention

Lines of transgenic mice have been developed which preferentially express a syndecan in the regions of the hypothalamus which are known to be important in weight control. The animals were made using a construct including a cytomegalovirus promoter and the 3' untranslated region, including the polyadenylation site, of the bovine growth hormone gene, as well as cDNA encoding syndecan-1. The mice express the syndecan-1 transgene in many tissues, with expression in the brain occurring preferentially in their hypothalamus. The mice are characterized by elevated levels of circulating syndecan-1 ectodomain and exhibit enormous weight gain after reaching sexual maturity. Transgenic animals in which stop codons have been inserted into the construct so that the syndecan is not expressed do not exhibit the same enormous weight gain. The animals have a relatively normal distribution of fat, are completely healthy and heterozygotes reproduce, and show other indicators associated with obesity in humans. The mice are useful in understanding the factors involved in weight regulation and in designing and screening for drugs which are involved in weight regulation and that can either enhance or reduce appetite and activity.

2025 RELEASE UNDER E.O. 14176

# BODY FAT REGULATION




FIG. 1




FIG. 2a






FIG. 2b



**FIG. 3a**



**FIG. 3b**



# MATURITY ONSET OBESITY CORRELATES WITH GENOTYPE

Male




FIG. 4a




FIG. 4b

# MATURITY ONSET OBESITY CORRELATES WITH GENOTYPE

Female




FIG. 5a





FIG. 5b

**TRANSGENIC MICE ARE LARGER THAN  
WILD TYPE CONTROLS AT SIX MONTHS OF AGE**



**FIG. 6**

# TRANSGENIC MICE ARE HYPERPHAGIC




FIG. 7




FIG. 8a

# FEMALE LEPTIN BLOOD LEVELS CORRELATE WITH OBESITY




FIG. 8b

# INSULIN PLASMA LEVELS ARE ELEVATED ONLY WITH EXTREME OBESITY




FIG. 9a

# Insulin plasma levels in females




FIG. 9b





# SYNDECAN-1 ECTODOMAIN IS DETECTED IN PLASMA FROM TRANSGENIC MICE




FIG. 11

# SYNDECANS AT THE CELL SURFACE




FIG. 12a

# SOLUBLE SYNDECANS IN THE EXTRACELLULAR SPACE




FIG. 12b

## DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below), or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Methods and Reagents for Regulating Obesity  
the specification of which (check one)

\_\_\_\_\_ is attached hereto

X was filed on November 6, 1997

as application Serial No. \_\_\_\_\_

\_\_\_\_\_ and was amended on: \_\_\_\_\_  
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)	Priority Claimed
_____ (Number)	_____ (Country)
_____ (Number)	_____ (Country)
_____ (Number)	_____ (Country)

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below:

Provisional Application Number

Filing Date

60/030,758  
(Number)

November 6, 1996  
(Day/Month/Year Filed)

\_\_\_\_\_  
(Number)

\_\_\_\_\_  
(Day/Month/Year Filed)

\_\_\_\_\_  
(Number)

\_\_\_\_\_  
(Day/Month/Year Filed)

Title " Methods and Reagents for Regulating Obesity  
By Merton Bernfield and Ofer Reizes  
Filed November 6, 1997  
DECLARATION

Full name of second inventor Ofer Reizes

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence 246 Watertown Street, Newton Massachusetts 02158

Citizenship United States

Post Office Address 246 Watertown Street, Newton, Massachusetts 02158

Full name of third inventor \_\_\_\_\_

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence \_\_\_\_\_

Citizenship \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of fourth inventor \_\_\_\_\_

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence \_\_\_\_\_

Citizenship \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of fifth inventor \_\_\_\_\_

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence \_\_\_\_\_

Citizenship \_\_\_\_\_

Post Office Address \_\_\_\_\_

Full name of sixth inventor \_\_\_\_\_

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence \_\_\_\_\_

Citizenship \_\_\_\_\_

Post Office Address \_\_\_\_\_

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of the application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	Status (patented, pending, abandoned)
--------------------------	---------------	------------------------------------------

(Application Serial No.)	(Filing Date)	Status (patented, pending, abandoned)
--------------------------	---------------	------------------------------------------

As named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Patrea L. Pabst	31,284
Suzanne F. Seavello	37,933
David S. Bradin	37,783
Collen A. Beard	38,824
Robert A. Hodges	41,074

Send Correspondence to: Patrea L. Pabst, Esq.  
ARNALL GOLDEN & GREGORY, LLP  
2800 One Atlantic Center  
1201 W. Peachtree Street  
Atlanta, GA 30309-3450

Direct telephone calls to: Patrea L. Pabst (404) 873-8794

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Merton Bernfield

Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence 25 Brimmer Street, Boston, Massachusetts 02158

Citizenship United States

Post Office Address 25 Brimmer Street, Boston, Massachusetts 02158